Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is ... NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.07 | 4.48717948718 | 1.56 | 1.63 | 1.5076 | 20079 | 1.57202831 | CS |
| 4 | 0.13 | 8.66666666667 | 1.5 | 1.68 | 1.38 | 21361 | 1.52795028 | CS |
| 12 | -0.48 | -22.7488151659 | 2.11 | 2.75 | 1.29 | 34908 | 1.94119133 | CS |
| 26 | -0.86 | -34.5381526104 | 2.49 | 2.75 | 1.29 | 102561 | 1.88986118 | CS |
| 52 | -0.86 | -34.5381526104 | 2.49 | 2.75 | 1.29 | 102561 | 1.88986118 | CS |
| 156 | -0.86 | -34.5381526104 | 2.49 | 2.75 | 1.29 | 102561 | 1.88986118 | CS |
| 260 | -0.86 | -34.5381526104 | 2.49 | 2.75 | 1.29 | 102561 | 1.88986118 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
